Analysis of hepatitis C viral kinetics and viramidine [taribavirin] pharmacokinetics utilizing two treatment regimens in therapy-naive patients with chronic hepatitis C

Trial Profile

Analysis of hepatitis C viral kinetics and viramidine [taribavirin] pharmacokinetics utilizing two treatment regimens in therapy-naive patients with chronic hepatitis C

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2012

At a glance

  • Drugs Taribavirin (Primary) ; Peginterferon alfa-2b
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Valeant Pharmaceuticals International
  • Most Recent Events

    • 21 Jun 2012 Additional lead trial investigator (Doyle RT) added as reported by ClinicalTrials.gov.
    • 03 Mar 2008 Planned end date 1 May 2007 added as reported by ClinicalTrials.gov.
    • 03 Mar 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top